122 related articles for article (PubMed ID: 22954251)
1. Advances in drug design with RXR modulators.
Vaz B; de Lera ÁR
Expert Opin Drug Discov; 2012 Nov; 7(11):1003-16. PubMed ID: 22954251
[TBL] [Abstract][Full Text] [Related]
2. Modulation of RXR function through ligand design.
Pérez E; Bourguet W; Gronemeyer H; de Lera AR
Biochim Biophys Acta; 2012 Jan; 1821(1):57-69. PubMed ID: 21515403
[TBL] [Abstract][Full Text] [Related]
3. Ligand Design for Modulation of RXR Functions.
Martínez C; Souto JA; de Lera AR
Methods Mol Biol; 2019; 2019():51-72. PubMed ID: 31359388
[TBL] [Abstract][Full Text] [Related]
4. Natural and Structure-based RXR Ligand Scaffolds and Their Functions.
Dominguez M; Alvarez S; de Lera AR
Curr Top Med Chem; 2017; 17(6):631-662. PubMed ID: 27320335
[TBL] [Abstract][Full Text] [Related]
5. Retinoid X Receptor Selective Agonists and their Synthetic Methods.
Wagner CE; Jurutka PW; Marshall PA; Heck MC
Curr Top Med Chem; 2017; 17(6):742-767. PubMed ID: 27320333
[TBL] [Abstract][Full Text] [Related]
6. Design of selective nuclear receptor modulators: RAR and RXR as a case study.
de Lera AR; Bourguet W; Altucci L; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):811-20. PubMed ID: 17906643
[TBL] [Abstract][Full Text] [Related]
7. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.
Fujii S; Ohsawa F; Yamada S; Shinozaki R; Fukai R; Makishima M; Enomoto S; Tai A; Kakuta H
Bioorg Med Chem Lett; 2010 Sep; 20(17):5139-42. PubMed ID: 20656484
[TBL] [Abstract][Full Text] [Related]
8. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis.
Sharma V; Hays WR; Wood WM; Pugazhenthi U; St Germain DL; Bianco AC; Krezel W; Chambon P; Haugen BR
Endocrinology; 2006 Mar; 147(3):1438-51. PubMed ID: 16306084
[TBL] [Abstract][Full Text] [Related]
9. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Leibowitz MD; Ardecky RJ; Boehm MF; Broderick CL; Carfagna MA; Crombie DL; D'Arrigo J; Etgen GJ; Faul MM; Grese TA; Havel H; Hein NI; Heyman RA; Jolley D; Klausing K; Liu S; Mais DE; Mapes CM; Marschke KB; Michellys PY; Montrose-Rafizadeh C; Ogilvie KM; Pascual B; Rungta D; Tyhonas JS; Urcan MS; Wardlow M; Yumibe N; Reifel-Miller A
Endocrinology; 2006 Feb; 147(2):1044-53. PubMed ID: 16269450
[TBL] [Abstract][Full Text] [Related]
10. Natural ligands of RXR receptors.
García P; Lorenzo P; de Lera AR
Methods Enzymol; 2020; 637():209-234. PubMed ID: 32359646
[TBL] [Abstract][Full Text] [Related]
11. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
12. Retinoid receptor subtype-selective modulators through synthetic modifications of RARgamma agonists.
Alvarez S; Alvarez R; Khanwalkar H; Germain P; Lemaire G; Rodríguez-Barrios F; Gronemeyer H; de Lera AR
Bioorg Med Chem; 2009 Jul; 17(13):4345-59. PubMed ID: 19482478
[TBL] [Abstract][Full Text] [Related]
13. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
Jurutka PW; Wagner CE
Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
[TBL] [Abstract][Full Text] [Related]
14. Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.
Zhang H; Li L; Chen L; Hu L; Jiang H; Shen X
J Mol Biol; 2011 Mar; 407(1):13-20. PubMed ID: 21262235
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities.
Lefebvre P
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):153-64. PubMed ID: 12476796
[TBL] [Abstract][Full Text] [Related]
16. Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology.
Lippert WP; Burschka C; Götz K; Kaupp M; Ivanova D; Gaudon C; Sato Y; Antony P; Rochel N; Moras D; Gronemeyer H; Tacke R
ChemMedChem; 2009 Jul; 4(7):1143-52. PubMed ID: 19496083
[TBL] [Abstract][Full Text] [Related]
17. Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference: RXRalpha-preferential agonist possessing a sulfonamide moiety.
Takamatsu K; Takano A; Yakushiji N; Morishita K; Matsuura N; Makishima M; Ali HI; Akaho E; Tai A; Sasaki K; Kakuta H
ChemMedChem; 2008 Mar; 3(3):454-60. PubMed ID: 18157857
[TBL] [Abstract][Full Text] [Related]
18. RAR and RXR modulation in cancer and metabolic disease.
Altucci L; Leibowitz MD; Ogilvie KM; de Lera AR; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):793-810. PubMed ID: 17906642
[TBL] [Abstract][Full Text] [Related]
19. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers.
Vivat V; Zechel C; Wurtz JM; Bourguet W; Kagechika H; Umemiya H; Shudo K; Moras D; Gronemeyer H; Chambon P
EMBO J; 1997 Sep; 16(18):5697-709. PubMed ID: 9312028
[TBL] [Abstract][Full Text] [Related]
20. Retinoid X receptor ligands: a patent review (2007 - 2013).
Yamada S; Kakuta H
Expert Opin Ther Pat; 2014 Apr; 24(4):443-52. PubMed ID: 24456080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
